Nurandociguat is a small molecule drug candidate that functions as a soluble guanylate cyclase activator, currently under investigation for its potential use in treating chronic kidney disease and various… Read more
Nurandociguat is a small molecule drug candidate that functions as a soluble guanylate cyclase activator, currently under investigation for its potential use in treating chronic kidney disease and various cardiovascular conditions. To support the rigorous research, clinical evaluation, and development of this therapeutic agent, pharmaceutical laboratories require high-quality reference standards. The available category includes essential analytical tools such as related impurity standards, metabolites, and stable isotope labelled compounds. These materials are critical for performing accurate impurity profiling, supporting comprehensive method validation, and maintaining consistent quality control throughout the manufacturing lifecycle. By utilizing these specialized reference compounds, analysts can effectively confirm the identity and stability of the active pharmaceutical ingredient, ensuring that all testing protocols meet the stringent requirements necessary for the advancement of this promising drug candidate.